Wednesday, 20 February 2013
Dublin, Tuesday 19 February 2013 … Biosensia Ltd., a point of care diagnostics company, today announces the appointment of James D. Merselis as Chief Executive Officer. Jim joins as the company seeks to secure regulatory approval for RapiPlex, its Point of Care platform, and continues to progress a pipeline of commercial deals.
Jim joined Biosensia in 2012 as a non-executive director, and will work closely with outgoing CEO Diarmuid Flavin to manage the transition. He is a non-executive director at Trinity Biotech (NASDAQ: TRIB) and has been a consultant to a range of healthcare companies. Jim was formerly President and CEO of ITC Nexus Dx, Inc, (acquired by Samsung Medical) a privately held diagnostics company working to improve patient care by providing rapid and reliable point-of-care medical test information. Prior to this, he served as President and CEO of Alverix, Inc, a privately held company developing portable medical diagnostic instruments.
Previous roles included, President and CEO of Hemosense Inc. (AMEX:HEM) (acquired by Alere), President and CEO of Micronics (acquired by SONY), and a number of positions with Boehringer Mannheim Diagnostics (now Roche Diagnostics).
Mr. Merselis said, “This is a great time to be joining Biosensia. RapiPlex is a fantastic platform, and will make a significant impact in the point of care or near patient testing market and other industries where sensitive information is needed in decentralized locations. With the initial product development now largely completed, we will be securing regulatory approval prior to product launch.”
Dr Jim Walsh, Chairman of Biosensia ltd., said: “We are very pleased to have Jim on board. He brings a wealth of experience in healthcare diagnostics and in particular the point of care space. This experience will be crucial as Biosensia continues to develop and RapiPlex reaches commercialisation.”
Over the past eighteen months, Biosensia has achieved a number of important milestones. The company raised a total €2 during that time, and July 2012 saw the company showcase the RapiPlex platform for the first time at the American Association of Clinical Chemistry (AACC) conference held in California. In addition, the company has registered its first patent, and is currently completing a new round of investment.
For further information, please contact:
Vicky La Touche-Price, Seroba Kernel Life Sciences: +353 1 6334028
Tel: +44 (0)7899 796655
Biosensia is development stage in vitro diagnostics company, focused on next generation point of care (POC) technology with a broad range of applications. Biosensia has developed RapiPlex®, a rapid, novel, multiplexing in vitro diagnostics platform, which is suitable for use in all immunoassay formats and for multiple applications including medical, environmental, food safety and security. Biosensia is an independent, venture capital funded company based in the Nova UCD incubation centre at University College Dublin, Ireland.